Sunil Parimi*, Jennifer Rauw and Jenny Ko Pages 1 - 14 ( 14 )
Testicular germ cell tumors (TGCTs) are unique to that of most other solid tumors because they are highly curable in the metastatic setting. While the use of cisplatin-based chemotherapy continues to drive cure in this patient population, important improvements in the delivery of therapy, creation of risk-adjusted treatment paradigms, and salvage-therapy options have further enhanced survival as well. The future holds promise for a more multidisciplinary approach to care, through advancements in biochemical markers and a better understanding of how surgical and radiotherapy approaches can integrate into our existing management strategies.
metastatic, systemic therapies, risk stratification, testicular germ cell tumor
BC Cancer Agency, Medical Oncology, BC Cancer Agency, Medical Oncology, BC Cancer Agency, Medical Oncology